Maze Therapeutics, Inc.
MAZE
$25.56
-$0.87-3.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -335.93% | -351.04% | -328.36% | -318.68% | 147.93% |
| Total Depreciation and Amortization | -28.64% | -27.12% | -26.88% | -25.32% | -23.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.03% | -13.21% | -25.13% | -5.69% | -12.86% |
| Change in Net Operating Assets | -667.09% | -49.24% | 80.61% | -578.39% | 9.98% |
| Cash from Operations | -273.93% | -247.38% | -237.16% | -229.91% | 180.17% |
| Capital Expenditure | 49.61% | 30.78% | -136.98% | -197.87% | -126.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -13,986.38% | -14,805.14% | -11,736.81% | -197.87% | -126.60% |
| Total Debt Issued | 15,112.74% | -- | -100.00% | -100.00% | -99.36% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 18.55% | 37,531.24% | 39,828.15% | 27,654.09% | 26,645.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 69.27% | 84.15% | 57.27% | -1,785.87% | -- |
| Cash from Financing | -2.72% | 196.55% | 782.08% | 379.10% | 378.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -136.17% | -104.51% | 44.16% | -26.33% | 664.84% |